Tokyo Tape
Sign in
← Suzuken

Quarterly report · Q3

9987.TEDINET S100Q7UC
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥1.76T2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥2.24T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.69T2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥24.4bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥12.8bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥27.3bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥23.4bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥15.4bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥27.0bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥18.7bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥18.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥14.4bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥13.2bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥18.1bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥13.3bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥1.30Tat 2022-12-31Cons.Assets
Total assets¥1.14Tat 2022-03-31Cons.Assets
Total assets¥1.29Tat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥891.5bnat 2022-12-31Cons.Liabilities
Total liabilities¥723.7bnat 2022-03-31Cons.Liabilities
Net assets / equity¥412.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥418.1bnat 2022-03-31Cons.Net assets
Net assets / equity¥419.7bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥169.8bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥141.4bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥208.462022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥85.552022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.192021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.022021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥46.252021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio31.6%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio32.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 40
SegmentItemPeriodValue
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥170.6bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥30.1bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥140.5bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.5bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥65.6bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥65.6bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10m
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.1bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥1.69T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥1.65T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥38.8bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥20.3bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥34.0bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥8.2bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥25.8bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥1.96T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥1.76T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥205.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥24.3bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥136.4bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥29.5bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥107.0bn
jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.8bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥66.8bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥66.8bn
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥20m
jpcrp040300-q3r_E02780-000The Insurance Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.6bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥1.62T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥1.58T
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥40.1bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥7.0bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥34.0bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥9.5bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥24.5bn
jpcrp040300-q3r_E02780-000The Pharmaceutical Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥2.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥1.86T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥1.69T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥171.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥12.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 354
ItemContextValueUnit
Selling general and administrative expensesCurrentYTDDuration110198000000JPY
Operating incomePrior1YTDDuration12827000000JPY
Operating incomeCurrentYTDDuration24416000000JPY
Interest income noiPrior1YTDDuration111000000JPY
Interest income noiCurrentYTDDuration116000000JPY
Dividends income noiPrior1YTDDuration1372000000JPY
Dividends income noiCurrentYTDDuration1162000000JPY
Equity in earnings of affiliates noiPrior1YTDDuration544000000JPY
Equity in earnings of affiliates noiCurrentYTDDuration1006000000JPY
Other noiPrior1YTDDuration857000000JPY
Other noiCurrentYTDDuration997000000JPY
Non operating incomePrior1YTDDuration2886000000JPY
Non operating incomeCurrentYTDDuration3282000000JPY
Interest expenses noePrior1YTDDuration40000000JPY
Interest expenses noeCurrentYTDDuration32000000JPY
Rent expenses on real estates noePrior1YTDDuration165000000JPY
Rent expenses on real estates noeCurrentYTDDuration226000000JPY
Other noePrior1YTDDuration122000000JPY
Other noeCurrentYTDDuration150000000JPY
Non operating expensesPrior1YTDDuration327000000JPY
Non operating expensesCurrentYTDDuration409000000JPY
Ordinary incomePrior1YTDDuration15385000000JPY
Ordinary incomeCurrentYTDDuration27289000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration823000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration9000000JPY
Gain on sales of investment securities eiPrior1YTDDuration7305000000JPY
Gain on sales of investment securities eiCurrentYTDDuration1000000JPY
Gain on transfer of business eiPrior1YTDDuration－JPY
Gain on transfer of business eiCurrentYTDDuration19000000JPY
Other eiPrior1YTDDuration23000000JPY
Other eiCurrentYTDDuration1000000JPY
Extraordinary incomePrior1YTDDuration8152000000JPY
Extraordinary incomeCurrentYTDDuration32000000JPY
Loss on sales and retirement of noncurrent assets elPrior1YTDDuration76000000JPY
Loss on sales and retirement of noncurrent assets elCurrentYTDDuration114000000JPY
Loss on valuation of investment securities elPrior1YTDDuration57000000JPY
Loss on valuation of investment securities elCurrentYTDDuration64000000JPY
Special retirement expenses elPrior1YTDDuration4659000000JPY
Special retirement expenses elCurrentYTDDuration14000000JPY
Other elPrior1YTDDuration32000000JPY
Other elCurrentYTDDuration109000000JPY
Extraordinary lossPrior1YTDDuration4826000000JPY
Extraordinary lossCurrentYTDDuration302000000JPY
Income before income taxesPrior1YTDDuration18711000000JPY
Income before income taxesCurrentYTDDuration27019000000JPY
Income taxesPrior1YTDDuration5383000000JPY
Income taxesCurrentYTDDuration8881000000JPY
Profit lossPrior1YTDDuration13327000000JPY
Profit lossCurrentYTDDuration18137000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration82000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass